Cue Biopharma, Inc. (FRA:1UC)

Market Cap	20.29M -64.3%
Revenue (ttm)	23.39M +195.7%
Net Income	-22.66M
EPS	-0.24
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	1,223
Open	0.1988
Previous Close	0.2130
Day's Range	0.1976 - 0.1988
52-Week Range	0.1976 - 0.9100
Beta	n/a
RSI	39.49
Earnings Date	Mar 31, 2026

About Cue Biopharma

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells in the United States. Its lead drug product candidate is the CUE-401, a bifunctional fusion protein designed to promote immune tolerance by inducing iTregs from Teff cells which is in preclinical trial; and CUE-501, a treatment of autoimmune disease via anti-viral T cell-mediated depletion of B cells. The company also develops CUE-101, which is in phase 1b clinic...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2014
• Employees: 29
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 1UC

Financial Performance

In 2025, Cue Biopharma's revenue was $27.47 million, an increase of 195.75% compared to the previous year's $9.29 million. Losses were -$26.60 million, -34.60% less than in 2024.

Financial numbers in USD